Dexamethasone-cyclophosphamide pulse therapy in pemphigus: A 5-year retrospective study
Keywords:Dexamethasone cyclophosphamide pulse (DCP), pemphigus, relapse
AbstractObjective The present work was conducted to assess the outcome of dexamethasone-cyclophosphamide pulse (DCP) therapy in pemphigus. Methods The present work was designed as a retrospective tertiary urban hospital based, observational study during the period from Jan 2012 to Dec 2016. Data regarding clinical details about the disease, previous treatments, phases of therapy, remission, relapse, cure, default and reasons for default, death and causes of death and adverse effects of therapy were evaluated. Results Out of 102 patients of pemphigus on DCP therapy, majority (n=42) of them belonged to age group of 40 to 49years. Mean age of patients was 42.08 years with a range of 24 to 65 years. Male to female ratio was 1:1.48. Of the 102 patients, 30 patients were in phase I, 23 were in phase II, 12 were in phase III and 37 were in phase IV. Mean number of pulses required for remission, that is, for completion of phase I were 5.2 months (range, 2-15 months). Majority (n=47, 65.3%) of them needed 4-7 pulses to achieve remission. Among 72 patients who achieved remission, a total 15 patient relapsed. Infusion-related reactions were the most common immediate adverse effect and generalized weakness/malaise were the most common delayed adverse effect recorded. Nine (7.7%) patients died while on DCP therapy and the most common (n=5) cause of death was septicaemia. Conclusion The DCP therapy was found to be effective in inducing and maintaining remission in pemphigus, provided the patients receive regular and complete treatment. The cost-effectiveness is definitely superior to other treatment modalities (biologics), which is of utmost importance in our setup as majority of patients belonged to poor socioeconomic strata, although the relapse rate and mortality rate were higher compared to other studies.
Diaz LA, Giudice GJ. — End of century overview of skin blisters. Arch Dermatol. 2000;136(1): 106-112.
Rao PN, Lakshmi TSS. Pulse therapy and its modifications in pemphigus: A six year study. Indian J Dermatol Venereol Leprol 2003;69:3293.
Pasricha JS, Poonam. Current regimen of pulse therapy for pemphigus: Minor modifications, improved results. Indian J Dermatol Venereol Leprol 2008;74:21721.
Mimouni D, Nousari CH, Cummins DL, Kouba DJ, David M, Anhalt GJ. Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris. J Am Acad Dermatol 2003; 49:1059–1062.
Pasricha JS. Pulse therapy as a cure for autoimmune diseases. Indian J Dermatol Venereol Leprol 2003;69:3238.
Sacchidanand S, Hiremath NC, Natraj HV, Revathi TN, Rani TS, Pradeep G et al . Dexamethasone cyclophosphamide pulse therapy for autoimmune vesiculobullous disorders at Victoria hospital, Bangalore. Dermatol Online J 2003;9:2.
S. Ikeda, S. Imamura, I. Hashimoto, S. Morioka, M. Sakuma, and H. Ogawa, “History of the establishment and revision of diagnostic criteria, severity index and therapeutic guidelines for pemphigus in Japan,” Archives of Dermatological Research, vol. 295, supplement 1, pp. S12–S16, 2003.
Pasricha JS, Khaitan BK, Raman RS, Chandra M. Dexamethasonecyclophosphamide pulse for pemphigus. Int J Dermatol 1995;34:87582.
Kandan S, Thappa DM. Outcome of dexamethasone cyclophosphamide pulse therapy in pemphigus: A case series. Indian J Dermatol Venereol Leprol 2009;75:3738.
Kanwar AJ, Kaur S, Thami GP. Longterm efficacy of dexamethasonecyclophosphamide pulse therapy in pemphigus. Dermatology 2002;204:22831.
Roy R, Kalla G. DexamethasoneCyclophosphamide pulse (DCP) therapy in pemphigus. Indian J Dermatol Venereol Leprol 1997;63:3546.
Ramam M. Dexamethasone pulse therapy in dermatology. Indian J Dermatol Venereol Leprol 2003;69:3192.,
Kanwar AJ, Ajith C, Narang T. Pemphigus in North India. J Cutan Med Surg 2006;10:215.
Jain R, Kumar B. Immediate and delayed complications of Dexamethasone Cyclophosphamide Pulse (DCP) therapy. J Dermatol 2003;30:7138.